|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Breathnach OS, Freidlin B, Conley B, Green
MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA and Johnson
BE: Twenty-two years of phase III trials for patients with advanced
non-small-cell lung cancer: Sobering results. J Clin Oncol.
19:1734–1742. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meng S, Zhou Z, Chen F, Kong X, Liu H,
Jiang K, Liu W, Hu M, Zhang X, Ding C and Wu Y: Newcastle disease
virus induces apoptosis in cisplatin-resistant human lung
adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett.
317:56–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network
(NCCN): NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®)Non-Small Cell Lung Cancer. NCCN; Fort
Washington, PA: 2015
|
|
6
|
Maroun JA, Anthony LB, Blais N, Burkes R,
Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent
MD and Wong R: Prevention and management of chemotherapy-induced
diarrhea in patients with colorectal cancer: A consensus statement
by the canadian working group on chemotherapy-induced diarrhea.
Curr Oncol. 14:13–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim JM, Park JW, Yoo HS, Lee YW and Cho
CK: Case report of the pancreatic cancer patient after
pancreatoduodenectomy who is taking the hangam-plus to
anti-metastasis and preventing recurrence. J Korean Tradit Onco.
16:33–39. 2011.
|
|
9
|
Kim KH, Park BR, Cho CK, Lee YW, Cho EJ,
Yea SC, Yoo BC and Yoo HS: Proteome alteration in human colon
cancer cells by the treatment of HangAmDan-B. Biochip J. 5:114–122.
2011. View Article : Google Scholar
|
|
10
|
Choi YJ, Shin DY, Lee YW, Cho CK, Kim GY,
Kim WJ, Yoo HS and Choi YH: Inhibition of cell motility and
invasion by HangAmDan-B in NCI-H460 human non-small cell lung
cancer cells. Oncol Rep. 26:1601–1608. 2011.PubMed/NCBI
|
|
11
|
Zheng HM, Yoon JW, Lee YW, Cho CK, Oh DS
and Yoo HS: Case series of advanced non-small cell lung cancer
patients treated with Hang-Am Plus. Korean J Orient Int Med.
32:113–120. 2011.
|
|
12
|
Kim KS, Jung TY, Yoo HS, Lee YW and Cho
CK: Case series of advanced non-small cell lung cancer patients
treated with Hang-Am-Plus. Korean J Orient Int Med. 30:893–900.
2009.
|
|
13
|
Park BK, Yoo HS, Lee YW, Han SS, Cho JH,
Son CG and Cho CK: Retrospective cohort analysis for lung cancer
patients treated with Wheel Balance Therapy (WBT). Korean J Orient
Int Med. 29:45–56. 2008.
|
|
14
|
Bang JY, Kim EY, Yoo HS, Lee YW, Kim YS,
Cho CK, Choi Y, Jeong HJ and Kang IC: Analysis of anti-angiogenic
mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine,
using antibody microarray chip. BioChip J. 4:350–355. 2010.
View Article : Google Scholar
|
|
15
|
Yoo HS, Lee HJ, Kim JS, Yoon J, Lee GH,
Lee YW and Cho CK: A toxicological study of HangAmDan-B in mice. J
Acupunct Meridian Stud. 4:54–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang HJ, Park SJ, Park YM, Yoo HS and Kang
IC: Inhibitory effects of HangAmDan-B1 (HAD-B1) on A549 lung cancer
cell proliferation and tumor growth in a xenograft model. Acad J
Sci Res. 4:187–193. 2016.
|
|
17
|
Bang JY, Kim EY, Kang DK, Chang SI, Han
MH, Baek KH and Kang IC: Pharmacoproteomic Analysis of a Novel
Cell-permeable Peptide Inhibitor of Tumor-induced Angiogenesis. Mol
Cell Proteomics. 10:M110.0052642011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fumagalli S, Totty NF, Hsuan JJ and
Courtneidge SA: A target for Src in mitosis. Nature. 368:871–874.
1994. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Molassiotis A, Fernadez-Ortega P, Pub D,
Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M,
Selvekerova S, et al: Use of complementary and alternative medicine
in cancer patients: A European survey. Ann Oncol. 16:655–663. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cragg GM and Newman DJ: Plants as a source
of anti-cancer agents. J Ethnopharma. 100:72–79. 2005. View Article : Google Scholar
|
|
22
|
Aoki Y, Feldman GM and Tosato G:
Inhibition of STAT3 signaling induces apoptosis and decreases
survivin expression in primary effusion lymphoma. Blood.
101:1535–1542. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lirdprapamongkol K, Sakurai H, Abdelhamed
S, Yokoyama S, Athikomkulchai S, Viriyaroj A, Awale S, Ruchirawat
S, Svasti J and Saiki I: Chrysin overcomes TRAIL resistance of
cancer cells through Mcl-1 downregulation by inhibiting STAT3
phosphorylation. Int J Oncol. 43:329–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Q, Hu J, Meng H, Shen Y, Zhou J and
Zhu Z: S-Phase cell cycle arrest, apoptosis, and molecular
mechanisms of aplasia ras homolog member i-induced human ovarian
cancer SKOV3 cell lines. Int J Gynecol Cancer. 24:629–634. 2014.
View Article : Google Scholar : PubMed/NCBI
|
